(Original title: Jiuzhou Pharmaceutical (603456.SH) intends to acquire 51% equity of Kangchuanji Medicine)
Zhitong Finance APP News, Jiuzhou Pharmaceutical (603456.SH) announced that the company intends to acquire 25.76% of Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. (“Kangchuanji Medicine”) with its own funds of 40 million yuan, and at the same time invest 80 million yuan Yuan increased the capital of the target company and subscribed for the newly increased registered capital of RMB 1.1332 million. After the transaction is completed, the company will hold 51% of the equity of Kangchuanji Pharmaceutical.
It is reported that Kangchuanji Medicine is a professional formulation research and development company, mainly engaged in CMC research of innovative drug formulations, research and development of new formulations of improved drugs, and consistency evaluation services. Kangchuanji Medicine also has the ability to undertake the delivery of samples for phase I and II clinical trials of innovative drugs.
According to the announcement, the acquisition of Kangchuanji Medicine will enhance the company’s ability to undertake the development of CDMO preparations and quickly promote the company’s one-stop business development for CDMO APIs and preparations.
.